Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers
Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers
复制标题
DOI：
10.1002/pros.10178
复制
发表时间：
2003-02-15
期刊：
影响因子：
2.8
通讯作者：
Shirai, T
中科院分区：
文献类型：
--
作者：
Takahashi, S;Suzuki, S;Shirai, T
背景我们以前进行了一个搜索的基因，差异表达在难治性前列腺癌的cDNA代表性差异分析（RDA）。前列腺素基因被分离出来，作为一个显示下调的肿瘤难治性癌症。在本研究中，检查了与前列腺肿瘤分期的联系。应用mRNA原位杂交、免疫组化及北方印迹分析方法检测54例前列腺癌组织中前列腺素的表达。通过北方印迹法，前列腺素在难治性癌症中的表达水平约为器官局限性癌症的六分之一。良性前列腺增生和高级别前列腺上皮内瘤变的腺体成分倾向于分别表现出轻度至中度和相对较强的强度。前列腺素mRNA和蛋白的表达水平均与前列腺癌的组织分化程度呈负相关，但与临床分期无关。几乎所有的转移性和难治性肿瘤的病例都表现出前列腺素表达的下调。这些结果表明，前列腺素不能被视为人类前列腺癌的预后指标，虽然它可能是一个有用的肿瘤分化的标志物。(C)2002 Wiley-Liss，Inc.
BACKGROUND. We previously conducted a search for genes which are differentially expressed in hormone-refractory prostate cancers using cDNA-representational difference analysis (RDA). The prostasin gene was isolated as one showing down-regulation in hormone-refractory cancers. In the present study, linkage to the stage in prostate neoplasia was examined.METHODS. Prostasin expressions in 54 prostate cancer cases were examined by mRNA in situ hybridization and immunohistochemistry as well as by northern blot analysis.RESULTS. Expression levels of prostasin in hormone-refractory cancers were approximately one-sixth of those in organ-confined cancers by northern blotting. Glandular components in benign prostatic hyperplasia and high-grade prostatic intraepithelial neoplasias tended to exhibit mild to moderate and relatively strong intensities, respectively. Expression levels of both prostasin mRNA and protein were inversely correlated with histological differentiation but not associated with clinical stage of human prostate cancer. Almost all cases of metastatic and hormone-refractory cancers demonstrated down-regulation of prostasin expression.CONCLUSIONS. These results suggest that prostasin cannot be regarded as a prognostic indicator for human prostate cancer although it may be a useful marker for tumor differentiation. (C) 2002 Wiley-Liss, Inc.